Evaluating the impact of cannabinoid extracts on chronic pain and quality of life in endometriosis patients - a pilot study.
Janosch W Kratz, Renata Voltolini Velho, Sandra Bock et al.
✦ AI-curated · Sources linked
In 30 seconds
This pilot study evaluated the effects of standardized oral cannabinoid extracts on chronic pain and quality of life in 30 premenopausal women with endometriosis. Significant improvements were noted in pain intensity (p = 0.0004), analgesic use, fatigue, anxiety, and overall quality of life after three months of treatment. The study employed a prospective single-center cohort design.
Key findings
- Pain intensity decreased significantly (p = 0.0004) after treatment.
- Analgesic use, including NSAIDs and opioids, reduced significantly (p < 0.001).
- Fatigue improved with a p-value of 0.0013.
- Anxiety and central sensitization showed significant reductions (p < 0.0001).
Why it matters
The findings suggest that cannabinoid-based medicinal products may offer a new adjunctive treatment option for managing chronic pain and improving quality of life in women with endometriosis, a condition often resistant to conventional therapies.
What to keep in mind
The study is limited by its single-center design, lack of placebo control, and short follow-up duration.